Bio-Rad Laboratories (TICKER: BIO) Benchmark And Performance Data

there are 11 of samples in the benchmark for Bio-Rad Laboratories in year 2022 in 2022. The total inventory for Bio-Rad Laboratories was $622,253,000.00 in 2020. The total inventory for Bio-Rad Laboratories was $594,804,000.00 in 2017. The total inventory for Bio-Rad Laboratories was $583,815,000.00 in 2018. The total inventory for Bio-Rad Laboratories was $572,239,000.00 in 2021. The total inventory for Bio-Rad Laboratories was $554,007,000.00 in 2019. The total inventory for Bio-Rad Laboratories was $524,961,000.00 in 2016. The total inventory for Bio-Rad Laboratories was $516,245,000.00 in 2013. The total inventory for Bio-Rad Laboratories was $490,224,000.00 in 2015. The total inventory for Bio-Rad Laboratories was $470,997,000.00 in 2014. The total inventory for Bio-Rad Laboratories was $455,120,000.00 in 2012. The sales, general, and administrative (SGA) for Bio-Rad Laboratories was $877,122,000.00 in 2021. The sales, general, and administrative (SGA) for Bio-Rad Laboratories was $834,783,000.00 in 2018. The sales, general, and administrative (SGA) for Bio-Rad Laboratories was $824,625,000.00 in 2019. The sales, general, and administrative (SGA) for Bio-Rad Laboratories was $814,697,000.00 in 2016. The sales, general, and administrative (SGA) for Bio-Rad Laboratories was $808,200,000.00 in 2014. The sales, general, and administrative (SGA) for Bio-Rad Laboratories was $806,790,000.00 in 2017. The sales, general, and administrative (SGA) for Bio-Rad Laboratories was $798,798,000.00 in 2020. The sales, general, and administrative (SGA) for Bio-Rad Laboratories was $798,070,000.00 in 2013. The sales, general, and administrative (SGA) for Bio-Rad Laboratories was $761,990,000.00 in 2015. The sales, general, and administrative (SGA) for Bio-Rad Laboratories was $681,778,000.00 in 2012. The sales, general, and administrative (SGA) for Bio-Rad Laboratories was $$828,000,000 in 2022. The revenue volatility for Bio-Rad Laboratories was 9.89% in 2022. The market capitalization for Bio-Rad Laboratories was $22,450,190,953.00 in 2014. The market capitalization for Bio-Rad Laboratories was $22,388,427,462.00 in 2013. The market capitalization for Bio-Rad Laboratories was $19,160,408,903.00 in 2012. The market capitalization for Bio-Rad Laboratories was $16,986,982,807.00 in 2015. The market capitalization for Bio-Rad Laboratories was $14,581,865,301.00 in 2016. The market capitalization for Bio-Rad Laboratories was $14,107,388,307.00 in 2019. The market capitalization for Bio-Rad Laboratories was $12,460,413,990.00 in 2018. The market capitalization for Bio-Rad Laboratories was $12,448,500,569.00 in 2017. The market capitalization for Bio-Rad Laboratories was $10,982,657,103.00 in 2020. The market capitalization for Bio-Rad Laboratories was $10,405,178,796.00 in 2021. The market capitalization for Bio-Rad Laboratories was $$9,323,000,000 in 2022. The gross revenue for Bio-Rad Laboratories was $2,922,545,000.00 in 2021. The gross revenue for Bio-Rad Laboratories was $2,545,626,000.00 in 2020. The gross revenue for Bio-Rad Laboratories was $2,311,659,000.00 in 2019. The gross revenue for Bio-Rad Laboratories was $2,289,415,000.00 in 2018. The gross revenue for Bio-Rad Laboratories was $2,175,044,000.00 in 2014. The gross revenue for Bio-Rad Laboratories was $2,160,153,000.00 in 2017. The gross revenue for Bio-Rad Laboratories was $2,132,694,000.00 in 2013. The gross revenue for Bio-Rad Laboratories was $2,069,235,000.00 in 2012. The gross revenue for Bio-Rad Laboratories was $2,068,172,000.00 in 2016. The gross revenue for Bio-Rad Laboratories was $2,019,441,000.00 in 2015. The gross revenue for Bio-Rad Laboratories was $$2,802,000,000 in 2022. The gross margin for Bio-Rad Laboratories was $16.95% in 2022. The days sales outstanding for Bio-Rad Laboratories was 60 days in 2022. The days payable outstanding for Bio-Rad Laboratories was 41 days in 2022. The days of inventory for Bio-Rad Laboratories was $191 in 2022. The cost of goods sold (COGS) for Bio-Rad Laboratories was 44.07% in 2022. The cost of goods sold (COGS) for Bio-Rad Laboratories was $996,527,000.00 in 2014. The cost of goods sold (COGS) for Bio-Rad Laboratories was $972,450,000.00 in 2017. The cost of goods sold (COGS) for Bio-Rad Laboratories was $954,216,000.00 in 2013. The cost of goods sold (COGS) for Bio-Rad Laboratories was $929,744,000.00 in 2016. The cost of goods sold (COGS) for Bio-Rad Laboratories was $914,077,000.00 in 2012. The cost of goods sold (COGS) for Bio-Rad Laboratories was $897,771,000.00 in 2015. The cost of goods sold (COGS) for Bio-Rad Laboratories was $1,284,449,000.00 in 2021. The cost of goods sold (COGS) for Bio-Rad Laboratories was $1,107,739,000.00 in 2020. The cost of goods sold (COGS) for Bio-Rad Laboratories was $1,066,264,000.00 in 2018. The cost of goods sold (COGS) for Bio-Rad Laboratories was $1,054,663,000.00 in 2019. The cost of goods sold (COGS) for Bio-Rad Laboratories was $$1,235,000,000 in 2022. The cash to cash cycle time for Bio-Rad Laboratories was 210 in 2022. The annual percentage growth rate of Bio-Rad Laboratories was 0.04% in 2022. Bio-Rad Laboratories in its benchmark peer group, had rank 9 for cost of goods sold as a percent of revenue in 2022. Bio-Rad Laboratories in its benchmark peer group, had rank 8 for cash to cash cycle time in 2022. Bio-Rad Laboratories in its benchmark peer group, had rank 7 days for days of inventory in 2022. Bio-Rad Laboratories in its benchmark peer group, had rank 6 days for days sales outstanding in 2022. Bio-Rad Laboratories in its benchmark peer group, had rank 2 for sales growth in 2022. Bio-Rad Laboratories in its benchmark peer group, had rank 10 for gross revenue in 2022. Bio-Rad Laboratories headquarters region is West. Bio-Rad Laboratories has ticker symbol BIO. Bio-Rad Laboratories has the following profile: Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety.. Bio-Rad Laboratories has primary indstury Medical Devices. Bio-Rad Laboratories had a $$932,000,000 gap between actual performance and next performance rank for gross revenue in competitive benchmarking in 2022. Bio-Rad Laboratories had Abbott Laboratories, and QuidelOrtho, and Zimmer Biomet, and Edwards Lifesciences, and Bio-Rad Laboratories, and Boston Scientific, and Align Technology, and Stryker, and AdaptHealth, and Bruker, and DexCom benchmark peer companies for its SIC code in 2022. Bio-Rad Laboratories had 8,200 number of employees in 2022. Bio-Rad Laboratories had 72 days gap between actual performance and next performance rank for cash to cash in competitive benchmarking in 2022. Bio-Rad Laboratories had 7 days gap between actual performance and next performance rank for days sales outstanding in competitive benchmarking in 2022. Bio-Rad Laboratories had 6.83% gap between actual performance and next performance rank for cost of goods sold as a percent of revenue in competitive benchmarking in 2022. Bio-Rad Laboratories had 32 days gap between actual performance and next performance rank for days of inventory in competitive benchmarking in 2022. Bio-Rad Laboratories had 1.06% gap between actual performance and next performance rank for gross margin in competitive benchmarking in 2022. Bio-Rad Laboratories had 0.00% gap between actual performance and next performance rank for sales volatility in competitive benchmarking in 2022. Bio-Rad Laboratories had 0.00% gap between actual performance and next performance rank for sales growth in competitive benchmarking in 2022. Bio-Rad Laboratories can reduce overall cost by $$297,000,000 by improving both COGS and SGA to next benchmark tier in 2022. Bio-Rad Laboratories can reduce inventory with practices including SKU Reduction in 2022. Bio-Rad Laboratories can reduce inventory with practices including Reduce Manufacturing Latency in 2022. Bio-Rad Laboratories can reduce inventory with practices including Forecast Accuracy in 2022. Bio-Rad Laboratories can reduce inventory with practices including Demand Shaping in 2022. Bio-Rad Laboratories can reduce days sales outstanding with practices including in 2022. Bio-Rad Laboratories can increase sales revenue by $$932,000,000 improving sales performance to next benchmark tier in 2022. Bio-Rad Laboratories can increase revenue growth by $$0 by improving growth performance to next benchmark tier in 2022. Bio-Rad Laboratories can increase overall revenue by $$932,000,000 by improving both growth and sales performance to next benchmark tier in 2022. Bio-Rad Laboratories can increase days payables outstanding with practices including Strategic Sourcing in 2022. Bio-Rad Laboratories can increase days payables outstanding by $146,000,000 days by increasing days payables outstanding to next benchmark tier in 2022. Bio-Rad Laboratories can improve total financial performance by $$1,675,000,000 by improving revenue, costs, and working capital in 2022. Bio-Rad Laboratories can decrease overall working capital by $$445,000,000 by improving inventory, payables and receivables to next benchmark tier in 2022. Bio-Rad Laboratories can decrease inventory days by $246,000,000 days by reducing inventory days to next benchmark tier in 2022. Bio-Rad Laboratories can decrease days sales outstanding by $54,000,000 days by reducing days sales outstanding to next benchmark tier in 2022. Bio-Rad Laboratories can accelerate revenue growth practices including in 2022. 94 days was the measured superior or top ten performance level for days of inventory in Bio-Rad Laboratories's peer group in 2022. 9.89% was the measured superior or top ten performance level for sales volatility in Bio-Rad Laboratories's peer group in 2022. 75 days was the measured superior or top ten performance level for cash to cash cycle time in Bio-Rad Laboratories's peer group in 2022. 60 days was the measured parity or middle performance level for days sales outstanding in Bio-Rad Laboratories's peer group in 2022. 53 days was the measured advantage or top third performance level for days sales outstanding in Bio-Rad Laboratories's peer group in 2022. 44 days was the measured superior or top ten performance level for days sales outstanding in Bio-Rad Laboratories's peer group in 2022. 37.24% was the measured parity or middle performance level for cost of goods sold as a percent of revenue in Bio-Rad Laboratories's peer group in 2022. 31.56% was the measured advantage or top third performance level for cost of goods sold as a percent of revenue in Bio-Rad Laboratories's peer group in 2022. 30.00% was the measured superior or top ten performance level for gross margin in Bio-Rad Laboratories's peer group in 2022. 29.10% was the measured superior or top ten performance level for cost of goods sold as a percent of revenue in Bio-Rad Laboratories's peer group in 2022. 159 days was the measured parity or middle performance level for days of inventory in Bio-Rad Laboratories's peer group in 2022. 138 days was the measured parity or middle performance level for cash to cash cycle time in Bio-Rad Laboratories's peer group in 2022. 13.32% was the measured parity or middle performance level for sales volatility in Bio-Rad Laboratories's peer group in 2022. 119 days was the measured advantage or top third performance level for cash to cash cycle time in Bio-Rad Laboratories's peer group in 2022. 11.40% was the measured advantage or top third performance level for sales volatility in Bio-Rad Laboratories's peer group in 2022. 108 days was the measured advantage or top third performance level for days of inventory in Bio-Rad Laboratories's peer group in 2022. 0.04% was the measured superior or top ten performance level for sales growth in Bio-Rad Laboratories's peer group in 2022. -0.05% was the measured parity or middle performance level for sales growth in Bio-Rad Laboratories's peer group in 2022. -0.02% was the measured advantage or top third performance level for sales growth in Bio-Rad Laboratories's peer group in 2022. $18.02% was the measured advantage or top third performance level for gross margin in Bio-Rad Laboratories's peer group in 2022. $17.18% was the measured parity or middle performance level for gross margin in Bio-Rad Laboratories's peer group in 2022. $$6,940,000,000 was the measured advantage or top third performance level for gross revenue in Bio-Rad Laboratories's peer group. $$3,735,000,000 was the measured parity or middle performance level for gross revenue in Bio-Rad Laboratories's peer group in 2022. $$18,449,000,000 was the measured superior or top ten performance level for gross revenue in Bio-Rad Laboratories's peer group in 2022.